| PerArdua Corporation | |||
| Proposed Ticker: | PRDU | 16 South Market Street | |
| Exchange: | NASDAQ-Small Cap Market | Petersburg, VA 23803 | |
| Industry: | Manufacturing (SIC Code 2836) | (804) 861-0681 | |
| Type of Shares: | Common Shares | Filing Date: | 2/5/97 | |
| U.S. Shares Filed: | 1,000,000 | Filing Price: | $5.00 | |
| Non-U.S. Shares Filed: | 0 | Offering Amount: | $5,000,000 | |
| Primary Shares: | 1,000,000 | Expenses: | $450,000 | |
| Secondary Shares: | 0 | Shares Out After: | 3,643,440 |
| Manager | Tier | Phone |
| Schneider Securities, Inc. | Lead Manager | (303) 837-9200 |
| Issuer's Law Firm: | LeClair, Ryan, Joynes, Epps & Framme |
| Bank's Law Firm: | Prifti, William M. |
| Auditor: | McGladrey & Pullen |
| Registrar/Transfer Agent: | American Stock Transfer & Trust Co |
Dollar amounts in U.S. millions except for per share data | |||||
| 6 Month Ending Financials | |||||
| Full Year Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 11/30/96 | 11/30/96 | ||||
| Revenue: | $0.00 | Assets: | $0.53 | ||
| Net Income: | -$2.09 | Curr Assets: | |||
| EPS: | -$0.81 | Liabilities: | $0.02 | ||
| Prior EPS: | -$0.55 | Curr Liabilities: | |||
| Cash Flow/Oper: | Equity: | $0.51 | |||
| Cash Flow/Fin: | Cash: | ||||
| Cash Flow/Inv: | |||||
| Business Description |
| The company is a development stage pharmaceutical company engaged in the development of a single anti-viral compound for which the company has adopted the trade name "Thiovir". The initial focus of the company's development activities will be to demonstrate the safety and efficacy of Thiovir for treatment of patients infected with human immunodeficiency virus (HIV), the virus which is the precursor to acquired immunodeficiency syndrome (AIDS), and patients showing active infection of the opportunistic virus cytomegalovirus which causes blindness and other conditions. CMV is primarily manifested among AIDS patients. The company believes that Thiovir, if successfully developed and approved for sale, would constitute a candidate for inclusion in combination drug therapy for HIV/AIDS treatment and would provide several benefits over existing treatments for CMV, particularly its potential ability to replace more toxic intravenous treatment with a less toxic oral treatment. The only development work on Thiovir to date has been limited to laboratory and animal studies conducted by unaffiliated organizations. Therefore, Thiovir is in an early stage of development. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used for research and development and working capital. |